7 Biotech Stocks to Buy on the Dip: June 2024
Fundamentally, the biotechnology sphere enjoys a powerful catalyst: wealth without health means nothing. Yes, it’s important to save money and invest for the future. At the same time, investing in o...
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
36.08 | |
35.68 | |
- | |
36.24 | |
35.68 | |
20.95-40.95 | |
1 174 M | |
14.2988 | |
32 715 K | |
567 M | |
1.45 | |
0.926 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Fundamentally, the biotechnology sphere enjoys a powerful catalyst: wealth without health means nothing. Yes, it’s important to save money and invest for the future. At the same time, investing in o...
Investing.com -- Here is your Pro Recap of the top takeaways from Wall Street analysts for the past week: upgrades for Best Buy , Lululemon and Collegium Pharma; downgrade for Maxeon Solar and Medifas...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: